Kailera raises $625M in upsized IPO for obesity peptide ribupatide
The Waltham company priced 39 million shares at $16, the top of its range, adding nearly six million shares to the planned offering.
TR
By Tom Reyes · Markets Editor
Apr 17 03:00 ETSource: MedCity News
The wire
- 01Kailera Therapeutics priced an upsized Nasdaq IPO at $16 a share for $625 million, funding a pipeline of injectable and oral obesity drugs led by ribupatide, a GLP-1 and GIP receptor agonist peptide.
- 02Ribupatide targets the same receptors as Eli Lilly's Zepbound; the company argues its once-weekly injectable has greater binding affinity and a longer half-life covering the full dosing interval.
- 03Three global Phase 3 trials are underway with preliminary data expected in 2028, so the differentiation claim rests on company assertions until those readouts.
From the source
Read at medcitynews.comKailera’s Upsized IPO Brings In $625M for Pipeline of Injectable & Oral Obesity Drugs
Kailera Therapeutics believes it can stand out in a crowded and competitive market for obesity medicines. Global clinical trials underway could help build the case for differentiation, and the company now has $625 million in IPO cash to support its pipeline of injectable and oral drugs through key data readouts.